loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.: bwire: the major problem at knh is structural and system failures
.
he has worked with patients under similar circumstances, but is not involved in the first lady’s case.
.
'indian ip and liabilities law barrier to pharma r&d investment'
.